Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Richard G. Glogau"'
Publikováno v:
Dermatologic Surgery
Supplemental Digital Content is Available in the Text.
BACKGROUND DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin in development that has demonstrated efficacy on dynamic glabellar lines. OBJECTIVE To evaluate the effect of r
BACKGROUND DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin in development that has demonstrated efficacy on dynamic glabellar lines. OBJECTIVE To evaluate the effect of r
Autor:
Jean D. Carruthers, Steve Fagien, John H. Joseph, Shannon D. Humphrey, Brian S. Biesman, Conor J. Gallagher, Yan Liu, Roman G. Rubio, Joel L. Cohen, Stephen Ho, Sue Ellen Cox, John Soderberg, Arthur Swift, Daniel Borsuk, Vasilios Papanastasiou, Ava Shamban, Soheil Simzar, Vince Bertucci, Brittany Waller, Charles Boyd, Molly Katz, Lauren Churchill, Stacy Smith, Cheryl Burgess, Karan Dhir, Zoe Draelos, Michael Draelos, Nathan Rosen, Channy Muhn, Ashish C. Bhatia, Shraddha Desai, Te-Shao Hsu, Christopher T. Kelly, Brandice M. Brazell, Jeanine Downie, Bruce Katz, Marianne Woody, Mary Lupo, Skylar Souyoul, Kavita Mariwalla, Joseph Eviatar, Wm. Philip Werschler, Scott Schade, Richard G. Glogau, Derek Jones, Jeanette M. Black, Naissan Wesley, Joely Kaufman-Janette, Joel Schlessinger, Jacqueline Hall, Shea Perillo, Jeffrey Dover, Laurel Morton, Nowell Solish, Gary Monheit, Heidi Essig, Steve Yoelin
Publikováno v:
Plastic and Reconstructive Surgery
Background: DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A formulation in clinical development. A phase 2 dose-ranging study identified an optimal dose and demonstrated efficacy with a median duration of 24 weeks. Methods:
Autor:
Richard G. Glogau, Laura Breshears, Jeffrey S. Dover, Steve Yoelin, Valerie D. Callender, Beta Bowen, Dee Anna Glaser, Jeremy B. Green
Publikováno v:
Dermatologic Surgery. 45:1531-1541
BACKGROUND ATX-101 (deoxycholic acid injection) is approved for reduction of moderate or severe submental fat (SMF). OBJECTIVE To evaluate the efficacy and safety of ATX-101 in subjects with mild or extreme SMF. PATIENTS AND METHODS Adults with mild
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB105
Publikováno v:
Toxicon. 190:S27-S28
Autor:
Richard G. Glogau, Eileen Axibal
Publikováno v:
Botulinum Toxins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7351d1a1062cbb2a01dc74f0064ce1e8
https://doi.org/10.1002/9781118661833.ch24
https://doi.org/10.1002/9781118661833.ch24
Autor:
Richard G. Glogau, Conor J Gallagher, Michael A. C. Kane, Carrie A. Caulkins, Christine Somogyi, Frederick C. Beddingfield, Xiaofang Lei
Publikováno v:
Dermatologic Surgery. 38:1794-1803
Duration of effect of aesthetic treatments with botulinum toxin potentially influences subject satisfaction, treatment frequency, and annual costs, but quantitative outcomes for measuring duration of effect and correlations with subject satisfaction
Autor:
Joel Schlessinger, Richard G. Glogau, Patrick Martin, Lisa Donofrio, Michael A. C. Kane, Ira Lawrence, Richard A. Baxter, Robert A. Weiss, Mark L. Jewell, Sue Ellen Cox, Jeffrey S. Dover
Publikováno v:
Aesthetic Surgery Journal. 32:868-876
Background: High-intensity focused ultrasonography (HIFU) is a nonsurgical, noninvasive method for body sculpting in nonobese patients. The technique ablates subcutaneous adipose tissue by causing molecular vibrations that increase tissue temperature
Autor:
Richard G. Glogau
Publikováno v:
Seminars in Cutaneous Medicine and Surgery. 31:78-87
Modern medical use of injectable soft-tissue augmentation fillers has evolved from the introduction of bovine collage implants to an array of synthesized materials in the current domestic and foreign markets. The concept of augmentation has moved fro
Autor:
Gary D. Monheit, Richard G. Glogau, Jacob M. Waugh, Andrew Blitzer, Rhoda S. Narins, Fredric S Brandt, Jean A. Paty, Michael A. C. Kane
Publikováno v:
Aesthetic Surgery Journal. 32:275-285
Background: Several scales have been employed for evaluating the effects of cosmetic treatments in the periorbital area. The Food and Drug Administration (FDA) has recently issued new recommendations specifying a rigorous process to validate new aest